Controlled Medicines in Indian Clinics: Schedule X, NDPS and Prescribing Boundaries
Separate drug classification, clinical assessment and permissions to possess or supply controlled medicines; build a product-specific review and stock handover.
Remote prescribing in India requires checking the current medicine list, consultation mode, first-or-follow-up status and whether the clinician has enough information. Read the 2020 telemedicine guidelines with subsequent medicine-list amendments. A video call, old prescription or “repeat patient” label does not automatically make a medicine or a remote treatment decision appropriate.
Registered medical practitioners, teleconsultation coordinators and clinic software buyers designing remote prescription and refill workflows.
Search results can mix the March 2020 guidelines, later medicine-list changes, professional commentary and the 2023 conduct regulations placed in abeyance. A clinic needs a dated source trail showing which rules informed its workflow. The newest-looking PDF title is not a sufficient basis for a prescribing policy.
Use the 2020 telemedicine framework together with relevant subsequent notifications and applicable drug law. NMC’s regulations index identifies the August 2023 abeyance notification. Check for later changes before operational use, rather than treating an old saved table as a permanently current permission list.
One important amendment is the MCI notice dated 11 April 2020, which added phenobarbitone, clobazam and clonazepam to List A for first and follow-up consultations. This named change is why a blanket statement about every psychiatric medicine or every medicine in a broad class can be misleading.
The amendment does not supply a treatment regimen or extend by analogy to other drugs. Keep the exact instrument and scope with the medicine-list record. Where classification or the interaction of rules is uncertain, obtain competent clarification before the affected prescribing decision.
Source: NMC regulations index: 2023 conduct regulations held in abeyance
The original guidelines distinguish List O, List A, List B and a prohibited category. Their baseline restriction covers Schedule X medicines and narcotic or psychotropic substances under the NDPS framework, read with specific amendments. “List X” is not a substitute name for these separate concepts.
The summary below is intentionally limited. It does not reproduce a comprehensive medicine catalogue, determine the status of a particular formulation or remove the need for adequate assessment. Check the current source for the exact medicine and encounter.
On a narrow screen, scroll the table horizontally to read all columns.
| Category | Framework distinction | Clinic review question |
|---|---|---|
| List O | May be considered through any consultation mode | Is the particular medicine in the current list and appropriate for this patient? |
| List A | First consultation by video; refill provisions for follow-up | Does the encounter meet the applicable conditions and any specific amendment? |
| List B | Additional treatment in qualifying follow-up for the same condition after in-person care | Is the prior care and current follow-up basis established? |
| Prohibited category | Not remotely prescribable under the applicable restriction | Have exact classification and any specific later amendment been checked? |
Source: MoHFW eSanjeevani: Telemedicine Practice Guidelines, 2020
A patient known to the clinic is not necessarily a follow-up for the same condition. A new complaint, a material change in symptoms, an unclear previous plan or a different treating relationship may require a different assessment. The appointment label should not decide the legal or clinical status of the encounter.
Retrieve the prior encounter and the actual treatment instructions. Record which condition is being reviewed, the relevant dates and clinician relationship, and check the guideline’s follow-up conditions. An image of an old medicine strip is useful information, but it does not establish every element of a qualifying follow-up.
Ask what has changed since the previous assessment: the patient’s account, treatment actually taken, new information and any barriers to care. Keep those answers in the clinical record rather than relying solely on a refill button that repeats the old order.
If the conditions are not established, do not manufacture them by backdating a visit or merging an unrelated consultation. The clinician should decide what assessment or referral is needed and explain the practical next step. Administrative convenience should not transform a new problem into a routine refill.
Even when a medicine passes a list check, the available consultation may be inadequate for a safe decision. A poor connection, uncertain identity, incomplete history or need for examination can make remote management unsuitable. The clinician should record the material limitation and the resulting plan.
A completed video connection proves that a call occurred; it does not prove that all relevant findings were assessed. Avoid documentation that automatically marks an examination normal because the visit mode was video. Record what could actually be observed and what could not.
Similarly, a medicine being excluded from remote prescribing does not mean that the patient should be abandoned or told to stop existing treatment abruptly. Arrange appropriate assessment and continuity through the treating professional. A coordinator should not suggest a substitute medicine to bypass a restriction.
Keep urgent-care routing usable. If the presentation needs prompt in-person assessment, the response should explain the relevant destination and urgency selected by the clinician. A promise to offer a later video slot may be an inadequate response to the actual situation.
Define what staff can collect before review: patient identity, contact route, prior document reference, medicine details as reported and the reason for the request. Collection is not authorisation. The staff script should avoid saying a refill is approved before a clinician reviews it.
The request may arrive from a caregiver or a pharmacy rather than the patient. Establish the relevant authority and communication arrangement. Do not assume that a forward of an old prescription gives the sender permission to receive every new clinical detail.
Route an uncertain medicine classification or missing prior record to the responsible professional. A well-designed queue should show why the request needs review and who owns it. Repeatedly passing the same message between reception and a doctor without an accountable next step leaves the patient in limbo.
Record the outcome in terms the patient can use: prescription issued after review, further information requested, in-person assessment arranged or another clinician-authorised plan. “Rejected” alone says little about what the patient should do or why the request could not be completed remotely.
The record should let another authorised clinician understand the basis for the remote decision. It need not contain an essay about every law, but it should preserve material facts about the consultation, previous care, assessment limits and the resulting plan.
Where a specific amendment or classification question matters, retain the relevant reference in the clinic’s controlled policy or product record. Do not paste a legal paragraph into every patient note as a replacement for the clinician’s reasoning.
The following outline is an original workflow aid. It is not a statutory form, a remote-prescribing permission or a clinical protocol.
A vendor may demonstrate a smooth remote visit with a preselected medicine and a complete patient history. Add cases that expose decision boundaries: an unverified prior prescription, a changed complaint, a failed video session and an exact drug whose classification needs review.
Ask who maintains medicine eligibility data, which sources they use and how an update reaches the clinic. A hard-coded list can become stale; an automatic update can also be wrong or insufficiently scoped. The clinic needs visibility into changes that affect prescribing decisions.
Inspect overrides and audit history. If an authorised exception process exists, it should preserve the reason and reviewer rather than making a restriction disappear without trace. Software should not encourage a clinician to select an inaccurate visit type to unlock an order.
Finally, test the patient handover. A correctly blocked order is only one part of the workflow; the patient still needs a clinician-approved next step. Use fictional data and a mock recipient to evaluate the complete process without generating real prescriptions or contacting patients.
A fictional Indore clinic receives a refill request from a patient previously seen for one condition. During the message exchange, a new concern emerges, and the previous prescription is not available in the record. The coordinator leaves the request for clinician review rather than marking it as a routine follow-up. The doctor decides what further assessment is needed and gives a clear next step. The example turns on the encounter’s actual basis; neither a saved contact nor a past clinic visit settles it.
Use these prompts in your clinic’s own notes. Record the result, responsible person and next action for each item.
Use the terminology in the applicable guideline and drug law. Schedule X is a drug-schedule concept; the telemedicine framework uses its own categories and a prohibited category. Confusing these labels can hide the need to check specific amendments and product classification.
The official April 2020 notice made a named medicine-list modification. A broad clinical class is therefore an unreliable shortcut. Review the exact medicine and current instruments instead of extending either a permission or a prohibition to every related product.
No. The clinician still needs adequate information and must assess the patient, the encounter conditions and the exact medicine. A functioning camera cannot resolve missing history, an examination limitation or an applicable prescribing restriction.
It is evidence to review, not automatic authorisation. Establish the prior care, current treatment, reason for the request and applicable follow-up conditions. A new concern or uncertain record may require a different assessment and plan.
Route the request to the responsible clinician, preserve the relevant facts and communicate the authorised next step. Do not recommend a substitute, promise supply or tell the patient to stop treatment solely because a software rule blocked the request.
Updated on . Workflow explanation for qualified practitioners. No exhaustive prohibited list, dose or treatment recommendation is supplied. Verify current instruments and obtain appropriate clinical or regulatory advice for the exact medicine and situation. No independent clinical or legal review is claimed.
Appendix 5 to the 2002 regulations. Read medicine lists alongside subsequent amendments, consultation conditions and applicable drug law; this is not a patient treatment protocol.
Adds phenobarbitone, clobazam and clonazepam to List A for first and follow-up consultations. A specific amendment does not establish permission for every medicine in the same class.
The official index identifies the 23 August 2023 abeyance notification. Check subsequent notifications and applicable council advice before adopting a legal position.
Separate drug classification, clinical assessment and permissions to possess or supply controlled medicines; build a product-specific review and stock handover.
Create a practical prescription-sharing process for shared phones, caregiver requests, corrected PDFs and wrong-recipient incidents in Indian clinics.
Turn clinician-selected warning signs into clear actions, destinations and review plans, including closed-clinic access and responsibility for pending results.
Ask Bractis to handle fictional remote requests with missing prior records, a failed video session and a classification question. Inspect the decision history and the patient’s next-step instructions, not only whether an order button is enabled.
Request a clinic demo